ILOPERIDONE (iloperidone) by Bayer is unknown. Approved for schizophrenia. First approved in 2016.
Drug data last refreshed 18h ago
unknown. However the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug.
Atypical Antipsychotic
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
Worked on ILOPERIDONE at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.